Inhibiting MEK in MAPK pathway-activated myeloma-Reference-Cited by-同舟云学术

Inhibiting MEK in MAPK pathway-activated myeloma

Published:2015-07-31 Issue:4 Volume:30 Page:976-980
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Heuck C J,Jethava Y,Khan R,van Rhee F,Zangari M,Chavan S,Robbins K,Miller S E,Matin A,Mohan M,Ali S M,Stephens P J,Ross J S,Miller V A,Davies F,Barlogie B,Morgan G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015208.pdf

Reference15 articles.

1. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

2. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.

3. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91–101.

4. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.

5. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384–390.

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-26

2. Functional Investigation of IGF1R Mutations in Multiple Myeloma;Cancers;2024-06-04

3. Approach to High-Risk Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Impact of Clonal Heterogeneity in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2023-01